Course Highlights Discover how combining lifestyle modifications with GLP-1 receptor agonists can improve weight loss, glycemic control, and overall cardiometabolic health Examine the science behind GLP-1 receptor agonists, from their effects on insulin secretion and appetite regulation to next-generation agents like tirzepatide and orforglipron Learn best practices for patient education, dosing strategies, and interprofessional collaboration while addressing contraindications, adverse effects, and compounding warnings Introduction Obesity is a chronic and prevalent condition that impacts health, contributing to higher rates of morbidity and mortality
No labs or video consults unless required by state law
Esser, N
A few programs (notably Eden Health and SHED) offer both pathways through the same platform
Some researchers interpret this as "the medication is not for me" rather than recognizing it as a timing problem specific to escalation
KG: Yeah, so the legislators who originally passed this law in 2023 are seeking to pass a law, again, that specifies coverage of GLP-1S for people who have a BMI of 35 or higher, and it would also guarantee continued coverage if those people were to lose weight fall below that BMI, as long as a doctor says, hey, if, if this person were to go off of this drug, they would likely regain the weight
